Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory biomarker study of guselkumab treatment response in psoriasis using multi-modal profiling
2019-002383-27Phase 4Terminated
- Sponsor
- Centre for Human Drug Research
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, double-blind trial of guselkumab in psoriasis, sponsored by Centre for Human Drug Research. Primary endpoint: Change over time in multi-modal biomarkers. Started Jun 2019; status: terminated.
02
Drugs
guselkumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2019-002383-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002383-27.